Data from epgonline.org - Curated by EPG Health - Last updated 02 August 2018

Accrediting Body

Union of European Medical Specialists (via European Accreditation Council for CME)

Award

1 credit

Subscription

Free

On completion of the activity, participants will:

  • understand the diagnostic and staging procedures as outlined in the 2015 ESMO CLL clinical practice guidelines including any updates from the 2011 version
  • appreciate the growing importance of identifying the genetic and IGHV status of patients and how this can help tailor treatment
  • understand the changing therapeutic landscape, the latest treatment recommendations including the amends made in the recent 2015 ESMO update, and current developments that may impact CLL management in future
  • recognise the importance of optimising patient treatment and understand how to manage adverse events to ensure patients get the most out of each therapy.
     

Category Value
Expiry date 31-Jul-20
Credit type Credit
Registration with provider required Yes
Certificate available Yes
Multi session Yes
Intended audience(s) Specialist
Assessment method(s) Multiple choice

Start CME

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Related Content